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K+ channels encoded by the ether-a-go-go related gene (ERG1 or KCNH2) are important
determinants of the cardiac action potential. Expression of both cardiac isoforms (ERG1a
and ERG1b) were identified in murine portal vein and distinctive voltage-gated K+
currents were recorded from single myocytes. The aim of the present study was to
ascertain the expression and functional impact of ERG channels in murine arteries.
Methods: Quantitative RT-PCR was undertaken on RNA extracted from a number
of murine arteries. Immunofluorescence was performed on single vascular smooth
muscle cells using antibodies against the ERG1 expression product (Kv11.1). Single
cell electrophysiology was performed on myocytes from portal vein and several different
arteries, complimented by isometric tension recordings. Proliferation assays were
undertaken on smooth muscle cells isolated from femoral arteries.
Results: ERG1 transcripts were detected in all murine blood vessels, and Kv11.1
immunofluorescence was observed in all smooth muscle cells. However, K+ currents
with properties consistent with ERG channels were only recorded in portal vein myocytes.
Moreover, ERG channel blockers (E4031 or dofetilide, 1 µM) failed to depolarize
carotid arteries or produce contraction. Proliferation of arterial smooth muscle cells was
associated with a marked increase in ERG1 expression and ERG blockers suppressed
proliferation significantly.
Conclusions: These data reveal that arterial blood vessels express ERG channels that
appear to be functional silent in contractile smooth muscle but contribute to proliferative
response.
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INTRODUCTION
The late repolarizing phase of the ventricular action potential is dictated by K+ flux through
voltage-dependent channels encoded by type 1 ether-a-go-go related genes (ERG1 or KCNH2)
and mutations to this gene underlie type 2 long QT syndrome arrhythmias (Curran et al., 1996).
Blockade of the hERG encoded channel (Kv11.1) underlie the majority of acquired arrhythmias.
Two major isoforms of ERG1 have been identified in mammalian hearts (Lees-Miller et al., 1997;
London et al., 1997; Pond et al., 2000), a full length variant (ERG1a) and a 340 amino acid
N-terminal truncated ERG1 (ERG1b; Lees-Miller et al., 1997; London et al., 1997). Over-expression
Barrese et al. Kv11 in Arteries
of both isoforms produces K+ currents with distinctive voltage-
dependent kinetics due to a dominating C-type inactivation
(Smith et al., 1996; Spector et al., 1996) and both isoforms are now
considered to contribute to the native cardiac current (Larsen
et al., 2008; Sale et al., 2008). Two other ERG genes (KCNH6 and
7, encoding for ERG 2 and 3 protein, respectively) exist, which
are predominantly expressed in the central nervous system. In
addition to the regulation of membrane potential, expression of
ether-a-go-go genes and ERG have been implicated in cellular
proliferation and oncogenesis (Babcock and Li, 2013).
In addition to the heart, hERG channels have been identified
in several cell types, including visceral smooth muscle (for a
review, see Vandenberg et al., 2012). ERG1 expression has been
identified in murine portal vein and single cell electrophysiology
revealed K+ currents with distinctive ERG kinetics that were
inhibited by the ERG blockers dofetilide, E-4031, or rBekm-
1 (Ohya et al., 2002; Yeung and Greenwood, 2007). However,
nothing is known about the expression of ERG in arterial
preparations and whether Kv11 channels contribute functionally
to smooth muscle activity in these blood vessels. Consequently,
we used quantitative PCR and immunofluorescence techniques,
in combination with single cell electrophysiology and whole
tissue isometric tension recordings, to explore the expression and
the possible functional role of ERG1-3 in a number of arterial
blood vessels.
MATERIALS AND METHODS
Experimental Models
All experiments were performed in accordance with the Animals
Act (1986) and St George’s Animal Welfare Committee approval
under Project license PPL 70/8512. Six to eight weeks old
female BALB/c mice were killed by intraperitoneal injection
with pentobarbitone, in accordance with schedule 1 of the
United Kingdom Animals Act (1986) and conforms with the
Guide and Care of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23,
1996). For studies looking at the proliferative smooth muscle,
arteries were taken from blood pressure normal (BPN) mice
(Jackson Laboratories, Bar Harbor, ME USA), that have been
used previously for such studies (e.g., Cidad et al., 2012). Mice
were killed by decapitation after isofluorane anesthesia using
protocols approved by the ethical committee of the University
of Valladolid and in accordance with the European Community
guiding principles. Blood vessels were excised and immediately
placed into RNA Later (Ambion) for RNA extraction or Krebs
for cell dispersal. Human Embryonic Kidney cells (HEK293)
were used for immunofluorescence studies. Cells were transiently
transfected with a plasmid encoding for mouse ERG using
lipofectamine 2000 (ThermoFisher, Paisley, UK), according to
manufacturer’s instructions.
Quantitative Polymerase Chain Reaction
Total RNA from mouse arteries were extracted using the method
described previously (Ohya et al., 2002; Yeung et al., 2007). One
microgram of RNA were reversed transcribed using the reverse
transcriptase (RTase) SuperScript
R©
II RNase H- (Invitrogen,
UK). All samples had a respective RT- control, i.e., no RTase was
put into the sample. The following PCR primers were used.
mERG1 (GenBank accession no. AF012868): 2,145–2,272,
amplicon = 128 bp (conserved region for both full length
ERG1a and the N-terminal truncated ERG1b): 5′-CCCCTC
CATCAAGGACAAGT-3′, 5′-TGAGCATGACACAGATGG
AG-3′; mERG1a (AF012868): 369–533, amplicon = 165 bp:
5′-CCTCGACACCATCATCCGCA-3′, 5′-AGGAAATCGCAG
GTGCAGGG-3′; mERG2 (NM_001037712), 328–468, 141 bp:
5′-GTGGATGTGGTCCCTGTGAA-3′; 5′-AGAGCCCAGGAA
GCTGTGTG-3′; mERG3 (AJ291608), 3,012–3,180, 169 bp:
5′-GCCCGGGCTCAACCTGAAGA-3′, 5′-TGGCCTGGATGT
CCGTTGTC-3′; glyceraldehyde 3-phosphate dehydrogenase
(mGAPDH, M32599): 492–599, amplicon = 108 bp: 5′-CCT
GCACCACCAACTGCTTA-3′, 5′-TCTTCTGGGTGGCAG
TGATG-3. Real time quantitative PCR was performed with the
use of Syber Green chemistry on an ABI 5700 sequence detector
(PE Biosystems). To study the changes on genes expression on
contractile vs. proliferative VSMCs the following TaqMan
R©
Assays (Applied Biosystems) were employed: (1) ERG1—
Kcnh2-Mm00465370_m1; (2) rRNA 18s—18S-Hs99999901_s1
(endogenous control). ERGs mRNA levels were normalized to
the housekeeping genes GAPDH or 18S and expressed using the
2−1Ct or 2−11Ct formulae.
Cell Dispersal
Single vascular smoothmuscle cells (VSMCs) were obtained from
portal vein (PV) and various arteries by enzymatic digestion in
physiological saline solution (PSS) containing (in mM) 60 NaCl,
6 KCl, 85 Na glutamate, 10 glucose, 10 HEPES, 2 MgCl2 0.1
CaCl2, adjusted to pH 7.4 with NaOH. The tissues were bathed in
1 mg/ml papain (Worthington, USA) and 1 mg/ml DTT (Sigma,
UK) made up in PSS containing 0 µM Ca2+ and maintained at
37◦C for 8.5 min. They were then transferred to another enzyme
mixture containing 0.5 mg/ml collagenase F (Sigma, UK) and 0.5
mg/ml collagenase H (Sigma, UK) made up in PSS containing
10 µM Ca2+ and also maintained at 37◦C for 8.5 min. Tissues
were then gently washed then triturated with ∼150 µl ice cold
PSS containing 50 µMCa2+.
Immunofluorescence
VSMCs and HEK293 cells were fixed with 3% paraformaldehyde
solution at 22–24◦C (RT) for 10 min, treated with 0.1 M glycine
for 5 min and incubated in blocking solution (PBS containing
0.1% Triton X-100 and 1% bovine serum albumin) for 1 h at RT.
Cells were then incubated overnight at 4◦Cwith a goat polyclonal
anti-HERG antibody (Santa Cruz, USA, dilution 1:100) or a
rabbit polyclonal anti-HERG antibody (Abcam, Cambridge, UK,
dilution 1:100), and mouse monoclonal anti-α-smooth muscle
actin antibody (dilution 1:1,000, Sigma, Dorset, UK). Samples
were then washed with PBS and incubated for 1 h with
donkey anti-goat or anti-rabbit secondary antibody conjugated
to Alexa Fluor 568 and donkey anti-mouse secondary antibody
conjugated to Alexa Fluor 488 (dilution 1:100, ThermoFisher,
Paisley, UK). All antibodies were diluted in blocking solution.
Subsequently, samples were washed with PBS and analyzed using
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a Zeiss LSM 510 Meta argon/krypton laser scanning confocal
microscope (Carl Zeiss, Jena, Germany).
Electrophysiology
ERG channels exhibit distinctive voltage-dependent kinetics that
are the product of a rapid inactivation dominating a slower
activation and deactivation. Similar to previous studies on mouse
portal vein smooth muscle cells (Ohya et al., 2002; Yeung and
Greenwood, 2007) we recorded whole cell K+ currents using the
ruptured patch configuration. Cells bathed in an external solution
containing 5 mM KCl were held at −50 mV and stepped to
+40 mV to activate voltage-dependent K+ channels and then
repolarized to various potentials from −120 to −20 mV (see
Yeung and Greenwood, 2007). In a further series of experiments
cells were bathed in an external solution containing 140 mM KCl
plus 10 mM tetraethyl ammonium and 5 mM 4-aminopyridine
to block non-ERG K+ channels held at 0 mV and stepped to
potentials between +20 and −120 mV (see Ohya et al., 2002).
With this protocol ERG channels exist in an inactivated state at
the holding potential and progressive hyperpolarization relieves
the inactivation and allows the channel to close resulting in the
distinctive hooked kinetics (e.g., Smith et al., 1996; Spector et al.,
1996; Ohya et al., 2002). The external solution for voltage-clamp
experiments contained (in mM): 126 NaCl, 5 KCl, 10 HEPES, 11
glucose, 1 MgCl2, and 0.1 CaCl2, adjusted to pH 7.2 with NaOH.
Where the external solution contained 140 mMKCl no NaCl was
present; all other constituents were identical, adjusted to pH 7.2
with KOH. The pipette (internal) solution contained (inmM) 130
KCl, 3 ATP Na+ salt, 0.1 GTP, 10 HEPES, and 1 MgCl2, adjusted
to pH 7.2 with KOH. All drugs were made up to 100 mM stock
solutions with either dimethyl sulfoxide (DMSO) or H2O.
Isometric Tension Recordings
Carotid arteries and aorta (CA and TA, respectively) were
cleaned of fat and 2 mm segments were mounted on 40 µm
tungsten wires in a small vessel myograph (DMT, Aarhus), which
contained 5 ml Krebs solution containing (in mM) 125 NaCl, 4.6
KCl, 2.5 CaCl2, 15.4 NaHCO3, 1 Na2HPO4, 0.6 MgSO4, and 10
glucose, maintained at 37◦C and continuously aerated with 95%
O2/5% CO2. Following equilibration, CA were normalized to a
tension equivalent to that generated at 90% of the diameter of
the vessel at 100 mmHg (Mulvany and Halpern, 1977). Segments
of aorta were set to a resting tension of 10 mN based on
previous optimization studies (Yeung et al., 2007) Tissues were
then bathed in Krebs solution containing 60 mM KCl for 5
min, repeated twice. Changes in tension were acquired using
PowerLab and Chart (version 5, ADInstruments, UK).
Membrane Potential Recording in Whole
Arteries
Membrane potential was measured continuously from whole CA
mounted in a wire myograph using borosilicate microelectrodes
(1.2 mm OD 0.69 I.D, World Precision Instruments, USA)
that had resistances between 80 and 120 M when filled with
2M KCl. Membrane potential (mV) was measured using an
amplifier (NL-102, Digitimer, United Kingdom) and recorded
on a using Powerlab 4/30 running Labchart 5 (AD instruments,
Australia). Electrode entry into a vascular smoothmuscle cell was
determined by an abrupt drop in voltage, followed by a sharp
return to baseline on exit, with a minimal change (no more than
10%) in resistance.
Smooth Muscle Cell Culture and
Proliferation
Dissected femoral arteries were cleaned of connective and
endothelial tissues, and placed in a 35 mm culture dish
covered with 2% gelatin (bovine skin type B, Sigma) in DMEM
supplemented with 20% FBS, penicillin-streptomycin (100 U/ml
each), 5 µg/ml fungizone, and 2 mM L-glutamine (Lonza) at
37◦C in a 5% CO2 humidified atmosphere. When cells reached
confluence, they were detached and seeded in a new culture plate
at a 1/3 density in D-MEM medium supplemented with 5% FBS,
penicillin-streptomycin (100 U/ml each), 5 µg/ml fungizone,
L-glutamine (2 mM), Insulin (5 µg/ml), bFGF (2 ng/ml), and
EGF (0.5 ng/ml). VSMCs were subjected to several passages
without showing morphological changes. For proliferation
assays, femoral VSMCs at passages 3–8 were seeded onto 12 mm
diameter poly-l-lysine coated coverslips placed in 12 mm wells
at a density of 25,000 cells/well and allow to attach in control
medium (5% FBS). Afterwards, cells were synchronized in serum
free (SF) medium during 48 h. Then, control media, alone or
in combination with various ion channel blockers/activators,
was added. Twenty-four hours post treatment, the percentage
of cells at the S phase was quantified using EdU (5-ethynyl-
2′-deoxyuridine) incorporation for an additional 6 h with a
commercial kit (Click-iT
R©
EdU Imaging Cell Proliferation
Assay, Invitrogen). Finally, cells were incubated with Hoechst
before mounting with Vectashield (Vector Laboratories Inc.,
Burlingame, CA). EdU incorporation was visualized with an
immunofluorescence microscope (Nikon) at the corresponding
wavelength depending on the Alexa Fluor
R©
used and expressed
as the percentage of the total cell number stained by Hoechst. In
each experiment, this percentage was obtained from the average
of 10–20 different fields per coverslip, and triplicates were made
for each condition.
Statistics
All data are expressed as mean ± s.e.m. One- or two-
way ANOVA test followed by Dunnett’s or Tukey’s post-
hoc analysis, and Student’s t-test were used to determine
statistical significance between groups, according to the different
experiments, using Graph Pad Prism software. Differences were
considered statistically significant when p< 0.05.
RESULTS
Kv11.1 Is Expressed in Vasculature
To date evidence for ERG expression in blood vessels is confined
to the mouse portal vein so quantitative PCR experiments were
undertaken on a range of murine arterial vessels. Transcripts
encoding for ERG1 were detected in aorta, carotid and femoral
arteries, as well as in portal vein (Figure 1A). Aorta and carotid
artery expressed higher levels of the full-length isoform (ERG1a)
than portal vein and femoral artery (Figure 1B). In contrast,
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FIGURE 1 | Expression of ERG in mouse vascular smooth muscle. (A,B) Results of quantitative PCR experiments showing expression of ERG1, 2 and 3 (A) and full
length ERG1a isoform (B) normalized to GAPDH expression in a range of vascular beds. Each column is the mean of 4 tissues ± s.e.m. Data are expressed using the
2−1Ct formula (C) Fluorescent images of smooth muscle cells from different vessels labeled with Kv11.1 antibody (left column) and smooth muscle actin (SMA,
middle column). Secondary antibodies only (no primary Abs) are shown at the bottom. Each image is representative of 3 separate dispersals. Scale bar = 5 µM.
ERG2 and ERG3 mRNA levels in these vessels were negligible
(n = 4 per vessel, Figure 1A). ERG2 and ERG3 transcripts were
also undetectable in mesenteric and pulmonary arteries (data
not shown). Immunofluorescence experiments were undertaken
to look at the expression and the cellular localization of Kv11.1
in myocytes isolated from murine aorta, carotid and femoral
arteries, and portal vein, using antibodies that specifically
detected Kv11.1 in HEK293 expressing mERG, but not in
untransfected cells (Supplemental Figure 1A). Smooth muscle
cells were identified by staining for α-smoothmuscle actin, which
adopted a peripheral localization (Figure 1C, green pseudocolor)
as reported previously (Shi and Sarna, 2013). Kv11.1 staining was
detected in VSMCs from all arteries and from portal vein, which
was predominantly located in or close to the cell membrane
(Figure 1C, red pseudocolor). Similar results were obtained in
immunofluorescence experiments with a different anti-Kv11.1
antibody (Supplemental Figure 1B).
Functional Role of Kv11 Proteins in Arterial
Myocytes
In previous studies on murine portal vein myocytes Kv11
channel K+ currents were characterized using bathing solutions
containing different concentrations of extracellular K+. In all
conditions the current was identified by the distinctive, “hooked”
voltage-dependent kinetics produced upon repolarization from a
depolarizing test step, as the channels recover from inactivation
and then close, and the sensitivity to known Kv11 channel
blockers dofetilide and E4031 (Ohya et al., 2002; Yeung
and Greenwood, 2007). We recorded similar currents with
hooked kinetics in portal vein cells bathed in external solutions
containing 5mMK+ and 140mMK+, which were abrogated by 1
µM dofetilide (Figures 2A–C). Figure 2B shows that in contrast
to portal vein myocytes, “hooked” currents were not present
in carotid artery myocytes from at least 5 different animals
regardless of whether the cell was bathed in an external solution
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containing 5 mM (n = 15), 35 mM (n = 10), or 140 mM KCl
(n = 6). A similar lack of distinctive, “hooked” currents was
observed in aortic myocytes from 10 different animals (data not
shown). The inhibitory effect of dofetilide seen in portal vein
myocytes was not observed in carotid artery cells (Figure 2D,
representative of 5 such records). These data suggest that Kv11
channel currents are not present in carotid or aortic smooth
muscle cells.
Effects of ERG Channel Activators
Recently a number of different compounds that activate ERG-
encoded K+ channels have been synthesized, including PD-
118057 and NS1643 (Zhou et al., 2005; Casis et al., 2006; Hansen
et al., 2006). It is possible that Kv11 channels are functional
in arterial myocytes but operate at very low levels of activity.
Consequently, experiments were undertaken to ascertain the
impact of the ERG channel activators, NS1643 and PD-118057,
on membrane currents in carotid artery myocytes. NS1643 (10
µM) augmented outward K+ currents at +40 mV in portal vein
myocytes, which was associated with a marked increase in the
amplitude and a slowing of the decay of the tail currents recorded
upon repolarization to −10 mV (Figures 3A,C,D) from 52 ±
3 to 120 ± 28 ms (n = 4). A second ERG activator, PD118057
(3 µM), produced similar effects consistent with previous study
in portal vein smooth muscle cells (Yeung and Greenwood,
2007). In carotid artery myocytes NS1643 had a negligible effect
on the current recorded at −100 mV (change from 9 ± 1.8
to 15 ± 2 pA, n = 5) but increased the outward current
considerably (Figures 3B–D). The stimulatory effect of NS1643
FIGURE 2 | Electrophysiological recordings in isolated vascular myocytes.
Examples of K+ currents recorded from portal vein (PV, A) or carotid artery
(CA, B) myocytes in external solutions containing either 5 mM K+ (i) or 140
mM K+ (ii). Voltage protocols shown as inserts. All scale bars represent 50 pA
and 50 ms. Panels (C,D) show representative traces in control conditions (gray
arrows) or in presence of 1 µM dofetilide (black arrows) on currents recorded
at −100 mV in PV (C) and CA (D) following a step depolarization from −50 to
+40 mV. All traces are representative of >5 cells from at least 3 animals.
on current measured in carotid artery was not sensitive to 1 µM
dofetilide (data not shown) but was inhibited by paxilline (1µM),
a blocker of large conductance, Ca2+-activated K+ channels
(BKCa; Figure 3E). PD118057 (3 µM) also had negligible effect
on currents recorded at −100 mV but enhanced currents at
+40 mV (Figures 3C,D) that was reversed completely upon
application of paxilline (138.7± 27.2% inhibition n= 3, data not
shown). These data suggest that in arterial myocytes, the ERG
activators NS1643 and PD-118057 stimulated large conductance
Ca2+-activated K+ channels but did not resurrect dormant ERG
channels.
Membrane Potential and Isometric Tension
Recordings in Whole Arteries
Whilst carotid artery and aortic myocytes lacked dofetilide-
sensitive K+ currents with characteristic “hooked” kinetics, this
did not entirely negate the possibility of a functional role for
ERG channels in an intact tissue system. In sharp microelectrode
studies on whole carotid arteries neither dofetilide (1 µM) nor
the Kv11.1 activator PD-118057 (3 µM) affected the resting
membrane potential (control:−52.8± 3.7 mV; dofetilide:−53.7
± 1.2 mV; PD-118057: −52.3 ± 2.2 mV) whereas addition of
the KATP activator levcromakalim (10 µM) produced marked
hyperpolarization (dofetilide+levcromakalim: −84.0 ± 3.9 mV;
PD-118057+levcromakalim: −74.0 ± 6.7 mV; Figure 4A).
Kv11.1 channel blockers increase contractile activity in a number
of visceral smooth muscle as well as the portal vein (Ohya et al.,
2002; Farrelly et al., 2003; Parr et al., 2003; Mewe et al., 2008;
Greenwood et al., 2009). In contrast, dofetilide (1 µM) did not
affect resting tone in carotid arteries (n= 8) and did not augment
the contractile response to 10 µM phenylephrine both in aorta
and carotid artery (Figure 4B). These data suggest that Kv11.1
proteins have little functional effect in arterial smooth muscle.
Kv11.1 Activation Promotes VSMCs
Proliferation
We next investigated the possible effects prompted by Kv11.1
modulation on arterial smooth muscle cells proliferation. We
first explored the expression levels of ERG1 in proliferating
smooth muscle cells from several vascular beds. To increase
specificity, these experiments were carried out with validated
Taqman probes. We compared ERG1 mRNA expression levels
between fresh tissue from aorta, femoral and mesenteric samples
(contractile VSMCs) and primary cultures of aortic, mesenteric
and femoral VSMCs (proliferating cells). When using the
abundance of the transcripts in the contractile VSMCs as
the calibrator, we found significantly higher levels of ERG1
transcripts in cultured VSMCs in all preparations, ranging from
a two-fold increase in mesenteric VSMCs to more than a 20-fold
increase in aortic VSMCs in culture (Figure 5A). We explored
if these changes in expression have some role in the phenotypic
switch of VSMCs by determine the possible contribution of
Kv11.1 to the proliferative response of the cultured VSMCs.
Under the experimental condition used to induce proliferation,
we found that smooth muscle cells isolated from femoral artery
showed a better response to the proliferating stimuli when
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FIGURE 3 | Effect of ERG channel activators on membrane currents. Examples of K+ currents evoked by membrane depolarization to +40 mV from −60 mV in the
absence and presence of 10 µM NS1643 recorded from a PV myocyte (A) and CA myocyte (B). Cells were repolarized to −100 mV after the test step to +40 mV.
The mean increase in currents at +40 and −100 mV produced by two structurally different ERG channel activators (10 µM NS1643 and 3 µM PD118057) is shown in
panels (C,D), respectively. Each panel is the mean of 4–7 cells. Black columns = PV and white columns = CA. Panel (E) shows the effect of 1 µM paxilline on
NS1643-stimulated currents at +40 mV in mCA myocytes (n = 8). Data are expressed as mean ± s.e.m. *p < 0.05 according to Student’s t-test.
compared to other arteries (data not shown). Therefore, for
the following experiments we focused on femoral VSMCs.
Incubation with 1 µM dofetilide decreased serum-induced
proliferation in cultured femoral by ∼30% compared to vehicle-
treated cells (from 22.46± 0.68 to 15.94± 0.97% of EdU positive
cells). In contrast, the ERG channel activator NS1643 (10 µM)
produced a ∼153% increase in VSMCs proliferation (to 34.49
± 2.1% of EdU positive cells), an effect that was fully abolished
when applied in combination with dofetilide. Treatment with the
BKCa blocker paxilline (1µM) did not affect VSMCs proliferation
(21.5 ± 1.0) and did not prevent NS1643-induced enhancement
of VSMCs proliferation (34.6± 1.6) (Figure 5B).
DISCUSSION
ERG-encoded Kv11 channels were once considered to be the
preserve of cardiomyocytes and neurons but recent studies have
shown that these channels are effective regulators of membrane
excitability and contractility in a number of smooth muscles
including esophagus, jejunum, gall bladder, urinary bladder,
epididymis, and uterus (Akbarali et al., 1999; Farrelly et al., 2003;
Parr et al., 2003; Mewe et al., 2008; Greenwood et al., 2009). In
each case the preparation in question is phasically active and
generates action potentials. In these tissues application of Kv11
channel blockers such as dofetilide, E4031 or cisapride increases
action potential duration, depolarizes the membrane potential
and augments spontaneous contractions inherent to these vessels.
These effects are associated with the abolition of a K+ current
with distinctive “hooked” kinetics characteristic of ERG channel
currents (Akbarali et al., 1999; Ohya et al., 2002). In addition,
to these visceral smooth muscles ERG1 expression has also been
identified in mouse portal vein where ERG channel currents have
been characterized in low and high external K+ (Ohya et al.,
2002; Yeung and Greenwood, 2007). Again, this tissue exhibits
spontaneous contractility and action potential discharge. This
study now reveals that a number of murine arteries, which do not
exhibit spontaneous contractions and action potentials, express
ERG1 but not ERG2 and ERG3, and that Kv11.1 subunits are
expressed in VSMCs from several arterial beds, where they seem
to localize at the plasma membrane levels. The expression and
role of ERG channels in arteries that developmyogenic tone, such
as cerebral artery, remain to be established. Our data also reveal
a differential expression of the full-length isoform (ERG1a), with
aorta and carotid artery showing higher levels compared to portal
vein and femoral artery. As total levels of ERG1 are relatively
higher in portal vein (Figure 1A), these data suggest that the
expression of ERG1b isoform might be more abundant in this
vessel, as described in previous studies (London et al., 1997; Pond
et al., 2000). ERG1b lacks 373 amino acids of the 1a isoform
and the N-terminus is replaced by a different 36-amino acid
sequence (Vandenberg et al., 2012), and recent evidence suggest
that incorporation of 1b isoform in the mature channels affect
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FIGURE 4 | Effect of ERG channel modulators on membrane potential in whole carotid arteries. (A) Mean membrane potential (Em) in carotid arteries in the absence
and presence of ERG blockers (1 µM dofetilide) and activators (3 µM PD118057). The ATP-sensitive K+ channel activator levcromakalim (10 µM) was applied as a
control. Each column is the mean of 4–8 arteries ± s.e.m. *p < 0.05, ***p < 0.001 according to one-way ANOVA. (B) Lack of effect of 1 µM dofetilide on contractions
induced by 10 µM phenylephrine in mouse aorta or carotid artery (mean ± s.e.m, n = 6). Statistical analysis has been performed using Student’s t-test (p > 0.05, non
significant).
Kv11.1 trafficking and sensitivity to endogenous mediators and
drugs (Phartiyal et al., 2008; Sale et al., 2008; Larsen et al., 2010).
Lack of Distinctive Ion Currents in Arterial
Myocytes
In the present study no dofetilide-sensitive K+ currents with
distinctive kinetics were recorded in carotid artery or aortic
myocytes, in contrast to portal vein myocytes (present study
and: Ohya et al., 2002; Yeung and Greenwood, 2007). This may
have been due to the dissociation process as ERG1-encoded K+
channels are degraded by serine proteases (Rajamani et al., 2006).
However, ERG channel currents have been recorded by various
laboratories in smooth muscle cells isolated by similar dispersal
techniques (such as portal vein, uterus, esophagus, Akbarali et al.,
1999; Ohya et al., 2002; Greenwood et al., 2009) including the
present study with portal vein myocytes. If this is the case then it
would suggest that for some reason the arterial Kv11.1 protein
is more susceptible to proteolytic degradation that the venous
Kv11.1 protein.
Functional Effects
ERG channel blockers failed to depolarize carotid arteries and
did not contract segments of aorta, carotid artery, or femoral
artery unlike the effect of these agents in spontaneously active
tissues described above. Dofetilide also had no effect on tone
in rat aorta, mesenteric, and intralobar arteries (Doggrell and
Nand, 2002) and does not raise mean arterial blood pressure
in dogs or monkeys (Haushalter et al., 2008). Thus, we believe
that ERG channels likely exist in arteries in a functionally silent
state due to underlying processing or regulation. Interestingly,
ERG channel blockers are spasmogenic in myometrium from
non-pregnant mice but are ineffective in myometrium from late
pregnant animals (Greenwood et al., 2009). This is associated
with an inability to record ERG channel currents in myocytes
dispersed from late pregnant myometrium, which are present in
myocytes from non-pregnant tissues (Greenwood et al., 2009).
This was not due to a decreased expression of Kv11.1 protein but
was associated with an increase in KCNE2 and KCNE4, which
encode for auxiliary subunits that alter the membrane abundance
and open probability of ERG channels (Abbott et al., 1999;
Mazhari et al., 2001;McCrossan and Abbott, 2004). Thus, the lack
of ERG channel function in arteries may be due to a suppressive
effect of the KCNE subunits expressed in the arteries, which we
have shown to be highly variable throughout the vascular tree
(Yeung et al., 2007). Alternatively, the different content of ERG1a
and 1b subunits of the tetrameric Kv11.1 channel may have an
impact on the membrane presentation of the mature channel, as
co-assembly increases the amount of channels in the membrane
and markedly increases current flow (Guasti et al., 2008). Portal
vein myocytes, which exhibited dofetilide-sensitive currents with
distinctive “hooked” kinetics expressed ERG1b at considerable
levels (Ohya et al., 2002).
Kv11 and Smooth Muscle Proliferation
In contrast to the lack of functional effects in contractile arteries,
ERG channel modulators had a marked impact on proliferating
arterial smooth muscle cells, with dofetilide retarding serum-
driven increase in cell number. Moreover, ERG1 expression
increased in proliferating arterial smooth muscle cells. Although,
we focused on femoral arteries as they responded better than
other arteries in our experimental conditions, we observed a
similar increase in ERG1 expression in other arteries as they
switched from contractile to proliferative states (Figure 5A).
The fact that the effects of NS1643 and dofetilide are mutually
canceled when used in combination, together with the lack of
effect of paxiline, a selective BK channel blocker, in preventing
NS1643-induced increase of proliferation excludes off-target
effects of the drugs, and in particular the contribution to these
effects on proliferation of a modulation of BK channels by
NS1643 as described above. These findings are in agreement with
many observations that ERG1 (KCNH2) and the closely related
EAG (KCNH1) have considerable oncogenic potential. Indeed,
ERG1 and EAG transcripts are up-regulated in tumor cells, while
pharmacological blockade or knock-down of ERG1 and EAG
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FIGURE 5 | Changes in the expression pattern of ERG channels in proliferating arterial smooth muscle. (A) Differences in expression of ERG1 in cultured femoral
VSMCs were calculated using 18S as housekeeping gene and the contractile VSMCs expression levels as calibrator, using the 2−11Ct formula, where 11Ct = 1Ct
proliferative −1Ct contractile and 2−11Ct represents the expression fold change. Each bar is the mean of 6–10 data from 3 to 5 assays in duplicate for each
condition. *p < 0.05; **p < 0.01; ***p < 0.001, according to Student’s t-test. (B) Proliferation rate (measured as % of cells incorporating EdU) of cultured femoral
VSMC in the absence of FBS, or in culture media supplemented with 5% FBS in the presence of vehicle (control condition) or the indicated drug combinations. **p <
0.01, ***p < 0.001 compared to control (vehicle), according to one-way ANOVA.
retards tumor cell proliferation (Arcangeli et al., 1995; Pardo
and Stühmer, 2014). Our findings suggest that altered ERG1
expression may contribute to disease-related smooth muscle
proliferation and implicates these ion channels as potential
targets as inhibitors of tumor driven neovascularization.
Limitations of the Study
In the present study we have used vessels from different strains
of mice. However, we checked that no differences in terms of
ERG expression and function were observed in BALB-C mice
and BPN mice prior to perform the proliferation experiments.
Whilst we observed an increase in ERG1 transcript levels in
proliferating VSMCs, we were unable to confirm these results
by evaluating Kv11.1 protein expression. Moreover, the resting
membrane potential was minimally affected by an ERG activator
and blocker in these cells (∼2 mV change). We were not able
to record any ERG-mediated current in proliferating VSMCs. It
should be noticed that similar results (i.e., lack of measurable
currents) have been observed in other experimental paradigms
evaluating the role of voltage-gated Kv7 channels in myoblasts
differentiation, despite a clear functional effects exerted by Kv7
modulators (Iannotti et al., 2010). Consequently, whilst the
effects of ERG modifying agents on cell number were clear, the
specific involvement of ERG1 in VSMCs proliferation needs to
be confirmed using more selective tools such as gene silencing.
Moreover, additional experiments should be performed to rule
out the role played by different ERG1 isoforms in this process.
CONCLUSIONS
This study reveals that Kv11.1 (commonly known as ERG)
is expressed in murine arteries, where localizes at the cell
membrane of smooth muscle cells but without exerting any
functional effect on vascular contractility and membrane
excitability. However, Kv11.1 channel modulators had
considerable effects on proliferating smooth muscle cells.
The mechanisms that make these channels functionally silent
in contractile smooth muscle and drive the increased ERG1
expression in proliferating arterial smooth muscle have not
been yet elucidated and need to be investigated in future
studies.
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